ACB logo

Aurora Cannabis Inc. (ACB)

$4.52

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on ACB

Market cap

$297461084

EPS

-1.1

P/E ratio

--

Price to sales

1.37

Dividend yield

--

Beta

0.658272

Price on ACB

Previous close

$4.61

Today's open

$4.59

Day's range

$4.49 - $4.62

52 week range

$2.56 - $6.36

Profile about ACB

CEO

Miguel Martin

Employees

1073

Headquarters

Edmonton, Alberta

Exchange

NASDAQ Capital Market

Shares outstanding

65745102

Issue type

Common Stock

ACB industries and sectors

Healthcare

Pharmaceuticals

News on ACB

Why Didn't Tilray Brands Make a Bid for Aurora Cannabis?

Tilray has been aggressively pursuing acquisitions in recent years. Its focus has largely been on loading up on craft brewers in the U.S. market.

news source

The Motley Fool • Nov 16, 2026

news preview

The Big Winner From the Aurora Cannabis-Organigram Deal: Curaleaf

Organigram is acquiring Aurora Cannabis. Curaleaf previously made multiple attempts to acquire Aurora in a hostile takeover.

news source

The Motley Fool • Nov 9, 2026

news preview

Aurora Cannabis Announces Fiscal 2027 Second Quarter Results

EDMONTON, Alberta--(BUSINESS WIRE)--Aurora Cannabis Inc. (the “Company” or “Aurora”) (NASDAQ | TSX: ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the second quarter 2027 ending September 30, 2026. Aurora has cancelled its investor call, originally scheduled for November 12, 2026, at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time, due to the Company's announcement on November 3, 2026, that Aurora has entered into a defin.

news source

Business Wire • Nov 5, 2026

news preview

Aurora Cannabis Inc. (ACB) Q2 Earnings and Revenues Top Estimates

Aurora Cannabis Inc. (ACB) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to earnings of $0.09 per share a year ago.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Aurora Cannabis Stock: What Organigram's Buyout Means for Investors

Aurora Cannabis shares surged after Organigram agreed to a C$561 million buyout, but competing bids, deal conditions and shareholder uncertainty remain.

news source

Zacks Investment Research • Nov 4, 2026

news preview

Curaleaf Issues Statement Regarding Alternative Proposal for Aurora Cannabis

STAMFORD, Conn., Nov. 3, 2026 /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf"), a leading international provider of consumer and medical cannabis products, today acknowledges the announcement by Aurora Cannabis Inc. (TSX: ACB) (NASDAQ: ACB) ("Aurora") of an alternative transaction from Organigram Global Inc. ("Organigram").

news source

PRNewsWire • Nov 3, 2026

news preview

Organigram to Acquire Aurora and Establish a Global Cannabis Leader

TORONTO & EDMONTON, Alberta--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) (“Organigram”) and Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) (“Aurora”) today announced that they have entered into an arrangement agreement (the “Arrangement Agreement”) pursuant to which Organigram will acquire all of the issued and outstanding common shares (the “Aurora Shares”) of Aurora at a price of C$7.80 per Aurora Common Share (the “Transaction”). The Transaction values Aurora at approxima.

news source

Business Wire • Nov 3, 2026

news preview

Aurora Cannabis to Host Second Quarter 2027 Investor Conference Call

EDMONTON, Alberta--(BUSINESS WIRE)--Aurora Cannabis Inc. (the “Company” or “Aurora”) (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today that it will host an investor conference call on Thursday, November 12, 2026 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time to discuss its financial results for the second quarter 2027. The Company will report its financial results prior to market open that same morning. Investor Conference Call Details DA.

news source

Business Wire • Oct 29, 2026

news preview

ACB's Q2 Earnings on Deck: International Medical Cannabis in Focus

Aurora Cannabis heads into Q2 earnings with revenues expected to fall 20.1%, as market exits and reimbursement cuts weigh on results while international medical cannabis markets offer support.

news source

Zacks Investment Research • Oct 27, 2026

news preview

Aurora Cannabis Announces the Alberta Securities Commission has dismissed Curaleaf's Application and ruled in favour of the Company's At-the-Market Program

NASDAQ | TSX: ACB Alberta Securities Commission dismisses Curaleaf's application concerning Aurora's ATM program. Curaleaf's unsuccessful application before the Alberta Securities Commission confirms Aurora's ATM program is compliant with Securities laws.

news source

PRNewsWire • Oct 26, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Aurora Cannabis Inc.

Open an M1 investment account to buy and sell Aurora Cannabis Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in ACB on M1